Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M748Revenue $M11.0Net Margin (%)-1,263.3Altman Z-Score1.3
Enterprise Value $M655EPS $-3.5Operating Margin %-1,271.9Piotroski F-Score1
P/E(ttm)--Beneish M-Score-4.3Pre-tax Margin (%)-1,263.3Higher ROA y-yN
Price/Book9.910-y EBITDA Growth Rate %-12.1Quick Ratio5.0Cash flow > EarningsY
Price/Sales82.35-y EBITDA Growth Rate %-3.8Current Ratio5.0Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-67.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-82.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M29.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with DVAX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
DVAXGeorge Soros 2012-06-30 Sold Out -0.03%$35.2 - $52.6
($42.76)
$ 25.51-40%Sold Out0
DVAXGeorge Soros 2012-03-31 Reduce-0.09%$32.8 - $50.3
($40.41)
$ 25.51-37%Reduce 62.50%37,500
DVAXGeorge Soros 2011-12-31 Buy 0.14%$18.2 - $33.3
($28.15)
$ 25.51-9%New holding100,000
DVAXGeorge Soros 2011-09-30 Sold Out -0.0026%$18.4 - $31.6
($24.39)
$ 25.515%Sold Out0
DVAXGeorge Soros 2011-06-30 Buy 0.0026%$24.6 - $28.1
($26.35)
$ 25.51-3%New holding6,610
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

DVAX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


DVAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Gray EddieCEO and Director 2014-08-14Buy2,500$14.958.19 view
KISNER DANIEL LDirector 2013-10-30Buy1,000$10.8118.24 view
ORONSKY ARNOLD LDirector 2013-10-30Buy18,605$10.8118.24 view
Phillips Peggy VDirector 2013-10-30Buy9,302$10.8118.24 view
Janssen RobertChief Medical Officer and VP 2013-07-09Sell0$0118.24 view
Novack David FSenior Vice President 2013-03-25Sell0$0118.24 view
COFFMAN ROBERTChief Scientific Officer & VP 2012-11-06Sell800$43.1-45.31 view
KESSEL MARKDirector 2012-10-16Sell600,000$47.3-50.17 view
COFFMAN ROBERTChief Scientific Officer & VP 2012-10-05Sell800$49.4-52.29 view
Lew JenniferVP, Finance & PAO 2012-09-14Sell1,875$45.3-47.97 view

Press Releases about DVAX :

Quarterly/Annual Reports about DVAX:

News about DVAX:

Articles On GuruFocus.com
Dynavax Secures $40 Million Credit Facility With Hercules Technology Growth Capital Dec 29 2014 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Dynavax Announces Webcast of R&D Day Dec 09 2014 
Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study Dec 08 2014 
Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of Coll Nov 28 2014 
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Nov 10 2014 
Dynavax Reports Third Quarter 2014 Financial Results Nov 05 2014 
Dynavax Announces Resignation of Dino Dina From Board of Directors Oct 15 2014 
Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma Oct 15 2014 
Two Promising Health Care Stocks with Market Capitalizations Under $500 Million Jun 11 2014 

More From Other Websites
RA Capital Is Expecting A Breakthrough Cancer Drug From This Biotech Jun 29 2015
Dynavax to Present at the William Blair 35th Annual Growth Stock Health Care Conference Jun 09 2015
Dynavax to Present at the William Blair 35th Annual Growth Stock Health Care Conference Jun 09 2015
Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog Jun 02 2015
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 01 2015
Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology... Jun 01 2015
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2015
DYNAVAX TECHNOLOGIES CORP Financials May 15 2015
10-Q for Dynavax Technologies Corp. May 09 2015
DYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
DYNAVAX TECHNOLOGIES CORP Files SEC form 10-Q, Quarterly Report May 07 2015
Dynavax Technologies reports 1Q loss May 07 2015
Dynavax Technologies reports 1Q loss May 07 2015
Dynavax Reports First Quarter 2015 Financial Results May 07 2015
Dynavax Reports First Quarter 2015 Financial Results May 07 2015
Under $2 Stock Could Make Traders 200%-Plus Profits May 06 2015
The Shuman Law Firm Investigates Dynavax Technologies Corp. Apr 17 2015
Dynavax to Present at the Cowen and Company 35th Annual Health Care Conference Mar 19 2015
Dynavax Announces Second Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM) Mar 19 2015
Dynavax to Present at the 2015 RBC Capital Markets' Global Healthcare Conference Mar 19 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK